Cantor Fitzgerald reiterates Agios Pharma stock rating ahead of PDUFA

Cantor Fitzgerald maintained an Overweight rating on Agios Pharmaceuticals (NASDAQ:AGIO) as the biotech firm gears up for an important regulatory milestone. With the stock currently trading at $30.97, InvestingPro analysis rates it as one of the Most Undervalued stocks. The firm keeps its bullish outlook on the company ahead of a November 1st PDUFA date for a drug candidate.

Cantor Fitzgerald is confident in Agios' assertion that the drug may secure approval without requiring a REMS program. Management also expressed optimism about the rapid commercial adoption of the drug if it receives approval, which they believe could outperform market expectations, similar to a previous success in the thalassemia market.

The company highlighted that sickle cell disease presents a more substantial market opportunity compared to thalassemia. This bullish sentiment is backed by Agios' impressive 141% revenue growth over the past year. However, InvestingPro Tips caution that the company is rapidly depleting its cash reserves. For a comprehensive understanding, investors can refer to the Pro Research Report available for AGIO and over 1,400 other US equities on InvestingPro.

Agios Pharmaceuticals recently reported its Q2 earnings, delivering a mixed performance. The company surpassed revenue expectations with $44.74 million in sales, compared to the estimated $26.57 million. Nonetheless, Agios reported a loss of $1.69 per share, slightly narrower than the expected loss of $1.65. The FDA granted priority review to the supplement new drug application for mitapivat, removing the need for an advisory committee meeting.

Cantor Fitzgerald has sustained its Overweight rating on Agios Pharma stock, demonstrating ongoing confidence in the company's potential. These updates illustrate recent achievements and hurdles encountered by Agios Pharmaceuticals.